Storys zum Thema Genetik

Schweizerischer Nationalfonds / Fonds national suisse

The tumour hacker

Schweizerischer Nationalfonds / Fonds national suisse

Victims of a tsunami or human sacrifice? What happened to these 20 Celts 2000 years ago?

Medison Pharma; Alnylam Pharmaceuticals

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Zug, Switzerland (ots/PRNewswire) - - The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance - Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient ...

Schweizerischer Nationalfonds / Fonds national suisse

She deciphers how tomato roots communicate

FDX Fluid Dynamix GmbH

4

FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiX

Schweizerischer Nationalfonds / Fonds national suisse

Wie Fadenwürmer altern - und was das für die Menschen bedeuten könnte

Bern (ots) - Ein Protein reduziert die Lebenserwartung von Fadenwürmern. Diese Entdeckung wirft die Frage auf, ob es beim Menschen ebenfalls den Alterungsprozess mitbewirkt. Selbst von den am besten erforschten Genen und Proteinen kennt man noch längst nicht alle Geheimnisse. Wie das Schweizer Taschenmesser haben sie zahlreiche, teilweise unbekannte Funktionen. Mit ...

Medison Pharma

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries

Zug, Switzerland (ots/PRNewswire) - - Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory ...

Schweizerischer Nationalfonds / Fonds national suisse

Fishing for DNA to measure biodiversity

Schweizerischer Nationalfonds / Fonds national suisse

Covid-19: Research findings form the basis for scientific communication with public authorities

Bern (ots) - Insights into Covid-19, recommendations for health authorities and vaccines: the findings and synthesis report for the Swiss National Science Foundation's National Research Programme "Covid-19" (NRP 78) were presented today. The Swiss National Science Foundation (SNSF) launched the National Research ...

MAVERICKS Life Co.

Latest Sports & Fitness Innovation: Holistic Training Syllabus by MAVERICKS Life Co.

CRANS-MONTANA, Switzerland (ots/PRNewswire) - Sports science & wellbeing education company, MAVERICKS Life Co., announces the release of its new Holistic Training Syllabus, rooted in evolutionary biology and epigenetics theory. It's a brand new innovation in the sports and fitness sector. Recent scientific studies* have led to groundbreaking development that is ...

Schweizerischer Nationalfonds / Fonds national suisse

The insatiable virus hunter

Lysando AG

Artilysin® - A Groundbreaking "Green Pharma" Solution

REVEAL GENOMICS, S.L.

REVEAL GENOMICS® ANNOUNCES POSITIVE TOP-LINE RESULTS FOR HER2DX® IN MEDSIR'S PHERGAIN TRIAL

Barcelona, Spain (ots/PRNewswire) - - HER2DX® pCR-score was significantly associated with pathological complete response in patients with HER2+ breast cancer treated with trastuzumab and pertuzumab, with or without chemotherapy. - HER2DX® risk-score identified 85% of patients with an invasive disease event as ...

Debiopharm International SA

DEBIOPHARM SHARES ONCOLOGY PROGRAM UPDATES AT ASCO 2023 FOR NOVEL WEE1 INHIBITOR, AND FIRST-IN-CLASS CA IX THERANOSTIC APPROACH

Lausanne, Switzerland (ots) - - Debiopharm will highlight diversified approaches and commitment to improving outcomes for patients with cancer at the 2023 American Society of Clinical Oncology Conference - A poster presentation and discussion will cover promising interim results with Debio 0123, a potent, highly ...

Debiopharm International SA

DEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER

Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...

Schweizerischer Nationalfonds / Fonds national suisse

The age of blood stains says more about the crime

Bern (ots) - The composition of blood stains changes over the course of weeks and months. Forensic medicine hopes to make use of this fact in future to convict suspects - or to prove their innocence. The blood-stained paper lay on the roof terrace for almost a year, protected from the rain but otherwise exposed to the elements. Fortunately it wasn't evidence of a violent crime; no, the drops of blood were part of a ...

Schweizerischer Nationalfonds / Fonds national suisse

Mosquitoes prefer cooler temperatures

Bern (ots) - Mosquitoes have thermal preferences. This is an important parameter to better predict outbreaks of diseases transmitted by these insects. "If they have a choice, when it's hot, mosquitoes hide in a cool place to rest," says Niels Verhulst, author of a study recently published in the journal Thermal Biology (*). The entomologist from the University of Zurich summarises the results of the experiment he ...

Grünenthal Group

Grünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...

Debiopharm International SA

DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS

Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...

Lysando AG

Amicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows

Schweizerischer Nationalfonds / Fonds national suisse

The Covid-19 pandemic is preparing us for future crises

Bern (ots) - The SNSF Corona Research Conference shows how the Covid-19 pandemic has enabled us to accumulate knowledge that will be useful in dealing with future crises. "If we ever have to deal with a new pandemic in future we will not be starting from scratch, as was the case when we were confronted with the coronavirus." These are the words of scientist Barbara Rath. As an active participant in the Vienna Vaccine ...

Grünenthal Group

Grünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research

Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...

Aurisco

Aurisco Expands Oligonucleotide Capacity and Launches New Website

SETÚBAL, Portugal (ots/PRNewswire) - The New State-of-Art OligoPilot 2000™ solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs. The new website shows how R&D and Innovation is the driving force of its sustainable growth, featuring its technologies, capabilities, services and products, including Oligonucleotides, peptides and small molecules ...

Aurisco

Aurisco Expands Oligonucleotide Capacity and Launches New Website

SETÚBAL, Portugal (ots/PRNewswire) - The New State-of-Art OligoPilot 2000TM solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs. The new website shows how R&D and Innovation is the driving force of its sustainable growth, featuring its technologies, capabilities, services and products, including Oligonucleotides, peptides and small molecules ...